Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
N-glycosylation by Mgat5 imposes a targetable constraint on immune-mediated tumor clearance
Erin E. Hollander, Rosemary E. Flock, Jayne C. McDevitt, William P. Vostrejs, Sydney L. Campbell, Margo I. Orlen, Samantha B. Kemp, Benjamin M. Kahn, Kathryn E. Wellen, Il-Kyu Kim, Ben Z. Stanger
Erin E. Hollander, Rosemary E. Flock, Jayne C. McDevitt, William P. Vostrejs, Sydney L. Campbell, Margo I. Orlen, Samantha B. Kemp, Benjamin M. Kahn, Kathryn E. Wellen, Il-Kyu Kim, Ben Z. Stanger
View: Text | PDF
Research Article Cell biology Oncology

N-glycosylation by Mgat5 imposes a targetable constraint on immune-mediated tumor clearance

  • Text
  • PDF
Abstract

The regulated glycosylation of the proteome has widespread effects on biological processes that cancer cells can exploit. Expression of N-acetylglucosaminyltransferase V (encoded by Mgat5 or GnT-V), which catalyzes the addition of β1,6-linked N-acetylglucosamine to form complex N-glycans, has been linked to tumor growth and metastasis across tumor types. Using a panel of murine pancreatic ductal adenocarcinoma (PDAC) clonal cell lines that recapitulate the immune heterogeneity of PDAC, we found that Mgat5 is required for tumor growth in vivo but not in vitro. Loss of Mgat5 results in tumor clearance that is dependent on T cells and dendritic cells, with NK cells playing an early role. Analysis of extrinsic cell death pathways revealed Mgat5-deficient cells have increased sensitivity to cell death mediated by the TNF superfamily, a property that was shared with other non-PDAC Mgat5-deficient cell lines. Finally, Mgat5 knockout in an immunotherapy-resistant PDAC line significantly decreased tumor growth and increased survival upon immune checkpoint blockade. These findings demonstrate a role for N-glycosylation in regulating the sensitivity of cancer cells to T cell killing through classical cell death pathways.

Authors

Erin E. Hollander, Rosemary E. Flock, Jayne C. McDevitt, William P. Vostrejs, Sydney L. Campbell, Margo I. Orlen, Samantha B. Kemp, Benjamin M. Kahn, Kathryn E. Wellen, Il-Kyu Kim, Ben Z. Stanger

×

Figure 2

Mgat5 glycans help cancer cells evade clearance by T cells in a cell-autonomous manner.

Options: View larger image (or click on image) Download as PowerPoint
Mgat5 glycans help cancer cells evade clearance by T cells in a cell-aut...
(A) Tumor volumes (mm3) over time of 2838c3 EV (n = 5) and Mgat5-KO-A subcutaneous tumors in the setting of either NK cell depletion (n = 10), CD4+/CD8+ T cell depletion (n = 10), or isotype control (n = 5). Data represent mean ± SEM. Statistical analysis done using 2-way ANOVA for this and all further tumor growth curves. (B) Growth (mm3) of 2838c3 EV and Mgat5-KO-A subcutaneous tumors in the setting of either CD4+ T cell depletion, CD8+ T cell depletion, or isotype control (n = 5 mice/group). Statistical analysis done on day 19. (C) Growth (mm3, left) and weights (right) of 2838c3 EV (n = 5) and Mgat5-KO-A (n = 6) subcutaneous tumors in Batf3–/– mice. Statistical analysis done using unpaired, 2-tailed Student t test for tumor weights. Data representative of 2 independent experiments. (D) Flow cytometric analysis of the indicated immune cell subsets in 2838c3 EV (n = 6) and Mgat5-KO-A tumors (n = 8) harvested on day 12 after subcutaneous injection. Data represent mean ± SEM. Statistical analysis using unpaired, 2-tailed Student’s t test. Data representative of 2 independent experiments. (E) Flow cytometric analysis of T cell cytotoxicity in draining lymph nodes (inguinal, axillary) from 2838c3 EV and Mgat5-KO subcutaneous flank tumor. Data represent mean ± SEM. Statistical analysis using unpaired, 2-tailed Student’s t test. Data representative of 2 independent experiments. (F) Growth (mm3) tumors following the injection of 2838c3 WT cells (n = 6), Mgat5-KO-A cells (n = 4), or a 1:1 mix of WT and KO cells (n = 7). (G) PHA-L staining by flow cytometry of the WT and 1:1 mixed WT + KO tumors. Statistical analysis done using unpaired, 2-tailed Student’s t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts